PharmaCyte Biotech, Inc. Common Stock
PMCBPharmaCyte Biotech, Inc. is a biotechnology company focused on developing cell therapy-based treatments for cancer and other serious diseases. The company leverages its proprietary live-cell encapsulation platform to create therapies that deliver targeted and sustained drug release, aiming to improve patient outcomes.
Company News
The pancreatic cancer treatment market is expected to grow significantly, driven by the increasing prevalence of the disease and the development of innovative therapies. Factors like the rising geriatric population, emerging chemotherapies, and increased healthcare investments in Asia-Pacific and the Middle East are further propelling the market ...
Meta Platforms, Inc. announced a whopping $40 billion share repurchase program.
Topics to Include Continued Analysis of FDA’s Clinical Hold on IND for Cell-in-a-Box® Topics to Include Continued Analysis of FDA’s Clinical Hold on IND for Cell-in-a-Box®
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (NASDAQ: ADGI) (IPOed Aug. 6) Alkermes plc (NASDAQ: ALKS) Bio-Rad Laboratories, Inc. (NYSE: BIO) Candel Therapeutics, Inc. (NASDAQ: CADL) (IPOed July 26) Century Therapeutics...
